The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Observational Studies of Salvage Treatment for Persistent Bacteremia: Beware of Survivor Treatment Selection Bias
Abstract
To the Editor—Jang et al [1] recently published an observational study on the efficacy of linezolid with or without carbapenem in salvage treatment for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. They found that the MRSA-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P=.030) and concluded that linezolid, with or without carbapenem, produces better outcomes for patients with persistent MRSA bacteremia. Although they may be right, their manuscript failed to mention a significant limitation of these findings: the survivor treatment selection bias. Indeed, as the introduction of linezolid was treated as a time-invariant factor in their analysis, the authors did not take into account the fact that patients who received linezolid may be different from those who did not, simply by virtue of having survived until the date of treatment alteration [2]. In other words, longer survival may increase the patient's probability of receiving linezolid and, thus, lead to a survivor selection bias. Of note, in the study by Jang et al [1], there was a trend toward a longer duration of bacteremia in patients treated with a linezolid salvage regimen, with a mean (± standard deviation) of 26.4±38.8 days, compared with 11.8±3.9 days in patients continually treated with a vancomycin-based regimen [1]. Although not statistically significant, which comes of no surprise given the small samples size and the wide dispersion of values, this trend suggests that survivor treatment bias may account for most of the survival benefit attributed to linezolid by the authors. Indeed, if the differences observed were related to the efficacy of the linezolid salvage regimen, one would expect a shorter duration of bacteremia in patients treated with linezolid, compared with patients who continued to receive a vancomycin regimen. Treatment survivor bias is common in studies published in top medical journals [3] and frequently affects key factors and conclusions [4]. To adequately address this issue, the authors should consider linezolid introduction as a time-dependent covariate in their analysis. Potential conflicts of interest. All authors: no conflicts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Linezolid was reported to be effective in the treatment of persistent MRSA bacteremia, 172 but this study had important study design weaknesses.173”
Citations
Cites
Time-dependent bias was common in survival analyses published in leading clinical journals
van Walraven, C., Davis, D., Forster, A. J., & Wells, G. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.12.008 · Cited by 337
Survivor Treatment Selection Bias in Observational Studies: Examples from the AIDS Literature
Glesby, M. J. M., & Hoover, D. R. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00008 · Cited by 194
Jang, H., Kim, S., Kim, K. H., Kim, C. J., Lee, S., Song, K., Jeon, J. H., Park, W. B., Kim, H. B., Park, S., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/600295 · Cited by 113 · cited 1×
“Indeed, as the introduction of linezolid was treated as a time-invariant factor in their analysis, the authors did not take into account the fact that patients who received linezolid may be different from those who did not, simply by virtue of having survived until the date of treatment alteration [2].”
BackgroundQuantifying the impact of survivor treatment bias in observational studies
Austin, P. C., Mamdani, M., van Walraven, C., & Tu, J. V. (2005) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2005.00624.x · Cited by 86
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Metadata
- Authors
- Tattevin, P., Uhel, F., & Fily, F.
- Affiliations
- Hôpital Pontchaillou (FR)
- Corresponding author
- Tattevin, Pierre
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-15
- Volume
- 49
- Issue
- 12
- Pages
- 1960-1961
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2147708573
- Cited by
- 4
- References
- 4
- Citations by year
- 2019: 1 · 2015: 1 · 2014: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Seoul
- College of Medicine, Seoul National University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- persistent bacteremia, MRSA bacteremia, salvage therapy, linezolid, carbapenems, vancomycin, treatment selection bias, duration of bacteremia, time-varying covariates, observational study limitations
- MeSH terms
- Linezolid, Acetamides, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Staphylococcal Infections, Vancomycin, Bacteremia, Salvage Therapy, Oxazolidinones, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Observational Studies of Salvage Treatment for Persistent Bacteremia: Beware of Survivor Treatment Selection Bias. https://app.cochat.ai/papers/10.1086/648500
- The paper
- Tattevin, P., Uhel, F., & Fily, F. (2009). Observational Studies of Salvage Treatment for Persistent Bacteremia: Beware of Survivor Treatment Selection Bias. Clinical Infectious Diseases. https://doi.org/10.1086/648500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.